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doi:10.1016/j.jaci.2012.03.005Subjects studied had EoE (n5 17), indeterminate EoE (n5 15),
gastroesophageal reflux disease (n 5 7), or normal esophagus
(n 5 21). EMT was analyzed for relationships to diagnosis,
eosinophil counts, and indices of subepithelial fibrosis,
eosinophil peroxidase, and TGF-b immunostaining. EMT was
assessed in pretreatment and posttreatment biopsy specimens
from 18 subjects with EoE treated with an elemental diet,
6-food elimination diet, or topical corticosteroids (n 5 6 per
group).
Results: TGF-b1 treatment of esophageal epithelial cells in vitro
for 24 hours induced upregulation of mesenchymal genes
characteristic of EMT, including N-cadherin (3.3-fold), vimentin
(2.1-fold), and fibronectin (7.5-fold). EMT in esophageal biopsy
specimens was associated with EoE (or indeterminate EoE) but
not gastroesophageal reflux disease or normal esophagus and
was correlated to eosinophil counts (r 5 0.691), eosinophil
peroxidase (r 5 0.738), and TGF-b (r 5 0.520) immunostaining
and fibrosis (r 5 0.644) indices. EMT resolved with EoE
treatments that induced clinicopathologic remission with
reduced eosinophil counts. EMT decreased significantly after
treatment by 74.1% overall in the 18 treated subjects with EoE;
pretreatment versus posttreatment EMT scores were 3.17 6
0.82 versus 0.82 6 0.39 (P < .001), with similar decreases within
treatment groups. Pretreatment/posttreatment EMT was
strongly correlated with eosinophil counts for combined (r 5
0.804, P < .001) and individual treatment groups.
Conclusions: EMT likely contributes to subepithelial fibrosis in
subjects with EoE and resolves with treatments that decrease
esophageal inflammation, and its resolution correlates with
decreased numbers of esophageal eosinophils. (J Allergy Clin
Immunol 2012;129:1387-96.)
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Eosinophilic esophagitis (EoE) has emerged as an increasingly
recognized immune-mediated food allergy– or aeroallergen-
associated chronic inflammatory disorder of the esophagus.1,2
Prolonged unbridled esophageal inflammation can lead to struc-
tural and functional changes, including thickening of the mucosa
and muscularis, dysmotility, decreased compliance, food impac-
tion, and strictures.3-5 A variety of clinical presentation patterns
ranging from feeding difficulties in toddlers to solid-food dyspha-
gia and food impaction in adolescents and adults suggests that
structural and functional changes might be part of the natural his-
tory of EoE.6 This is further supported by pediatric studies show-
ing that subepithelial fibrosis occurs in greater than 50% of1387
J ALLERGY CLIN IMMUNOL
MAY 2012
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reactionSFED: Six-food elimination dietTC: Topical corticosteroidchildren with EoE.7,8 Understanding the mechanisms leading to
subepithelial fibrosis in patients with EoE could lead to identifica-
tion of novel therapeutic targets.
Epithelial mesenchymal transition (EMT) describes a series of
events during which epithelia losemany epithelial characteristics,
including polarity, expression of epithelial markers, and tight
junctions, and acquire properties of mesenchymal cells, including
motility, loose cell adhesion through N-cadherin, and depolarized
cytoskeletal arrangements, such as vimentin.9 EMT facilitates the
development of tissue fibrosis in different organ systems in re-
sponse to injury and chronic inflammation and is associated
with the development of fibrosis in the kidney, lung (idiopathic
pulmonary fibrosis and asthma), liver, heart (cardiac fibrosis),
and gastrointestinal tract (Crohn disease).10-12 Whether EMToc-
curs in the esophagus and contributes to subepithelial fibrosis and
remodeling in patients with EoE has not been explored.
The purposes of this study were to determine whether EMT
occurs in children with EoE and, if successful, whether treatment
of EoE (symptoms and histologic remission) results in resolution
of EMT. Results demonstrate that EMT occurs to a significantly
greater degree in the esophageal tissues of children with EoE
compared with those of children with gastroesophageal reflux
disease (GERD) or those with normal esophageal tissue. The
degree of EMT correlates with traditional measures of esophageal
inflammation and remodeling in patients with EoE, including
eosinophil number, expression of remodeling factors (TGF-b),
and extent of subepithelial fibrosis. EMT resolves in patients with
EoE in response to treatments that decrease esophageal inflam-
mation, as characterized by decreases in eosinophil burden.METHODS
Cell culture and induction of EMT in vitro
Human esophageal epithelial HET-1A cells (American Type Culture
Collection, Manassas, Va) were maintained in Bronchial Epithelial Growth
Media without gentamycin-amphotericin B (Lonza/Clonetics, Walkersville,
Md). For mRNA analysis, cells at confluence in 6-well plates were cultured an
additional 24 or 48 hours in fresh media with or without 5 ng/mL TGF-b1
(R&D Systems, Minneapolis, Minn). Expression of mRNAs encoding adhe-
sion and cytoskeletal proteins representative of epithelial cells (E-cadherin,
cytokeratin 8, and cytokeratin 14) and mesenchymal cells (N-cadherin,
vimentin, and fibronectin) as biomarkers of EMT were analyzed in total
RNA by using real-time quantitative RT-PCR (RT-Q-PCR).RT-Q-PCR
Total RNAwas prepared by using QIAshredder columns and the RNeasy
Mini RNA Isolation Kit (Qiagen, Valencia, Calif), and cDNAwas synthesizedby using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, Calif).13 Briefly, from 500 ng of RNA, gene transcripts were assessed by
using TaqMan Gene Expression Assay FAM dye-labeled TaqMan MGB
probes (Applied Biosystems; see Table E1 in this article’s Online Repository
at www.jacionline.org) and ABsolute Blue QPCR ROX MasterMix (Thermo
Scientific, Surrey, United Kingdom). Thermocycling and analysis was per-
formed with an ABI-7300 system. Data were normalized to 18S expression
and calculated as relative quantity (22DDCt, where Ct is defined as the cycle
threshold).
Study populations and design: Clinical biopsy
specimens
A retrospective analysis of 890 archived esophageal biopsy specimens
from pediatric subjects at Children’s Hospital Colorado from 2006 was
performed. Of these, tissue sections from 60 subjects’ biopsy specimens
with more than 2 mm of lamina propria were analyzed based on the
following: (1) availability of sufficient formalin-fixed, paraffin-embedded
tissue and (2) the subject’s diagnosis of EoE, indeterminate EoE, GERD, or
normal esophagus. Diagnostic criteria were as follows: active symptomatic
EoE, 15 or more eosinophils/high-power field (hpf) and other causes
excluded; indeterminate symptomatic EoE, less than 15 eosinophils/hpf and
clinical features suggestive of EoE or clinical features of EoE and 15 or
more eosinophils/hpf without documented treatment with proton pump
inhibitors (PPIs) or pH probe to exclude GERD1,14; GERD–PPI-responsive
esophagitis, less than 15 eosinophils/hpf; and healthy control subjects, sub-
jects undergoing clinically indicated endoscopy but with an endoscopically
and histologically normal esophagus.
Eighteen pediatric subjects with EoEwere randomly selected from the EoE
patient database at Children’s Memorial Hospital in Chicago who had
achieved histologic remission after treatment with an elemental diet (ED),
empiric 6-food elimination diet (SFED), or topical corticosteroids (TCs) to
assess the effect of treatment on EMT (n5 6 per group). Diagnostic criteria for
EoE were as above, with histologic remission defined as 10 or fewer
eosinophils/hpf. Posttreatment biopsy specimens were obtained from the
mid and distal esophagus after at least 6 weeks of treatment and pretreatment
and posttreatment tissue sections immunostained for EMT.
Assessment of EMT: EMT index
Three-color immunofluorescence and confocal microscopy were used to
identify and evaluate epithelial and mesenchymal cells by using cytokeratin
(epithelial), vimentin (mesenchymal), and 49-6-diamidino-2-phenylindole
dihydrochloride (nuclear) stains in esophageal biopsy tissue sections.
A 6-point scale was developed to score the amount of EMT, assessing the
presence, location, and degree of vimentin-positive mesenchymal cells and
loss of cytokeratin staining of epithelial cells in the context of hyperplastic
changes in epithelial architecture (Fig 1). Confocal microscopy was used to
acquire fluorescent images of 18 to 25 hpfs covering the entirety of each tissue
section. Confocal images of stained sections were analyzed in a blinded man-
ner by 2 independent observers (N.A. and K.R.P.) and scored for EMT; mean
EMT indices per hpf were calculated.Assessment of eosinophil counts in biopsy
specimens
Eosinophils in hematoxylin and eosin–stained slides were quantified in
hpfs (area, 0.26 mm2) by counting the 5 most densely populated regions of the
tissue, and peak (highest in single section) and mean values were recorded.Anti–eosinophil peroxidase
immunohistochemistry: Eosinophil peroxidase
index
Sections from esophageal biopsy specimens were stained with anti-
eosinophil peroxidase (EPX) mAb (hybridoma MM25-82.2.1; Mayo Clinic,
Phoenix, Ariz).15 On the basis of the presence of eosinophils, evidence of
FIG 1. Six-point EMT assessment scale for quantitation in esophageal biopsy specimens. Representative
merged confocal images of immunofluorescent staining for cytokeratin (green) and vimentin (red)with 49-6-
diamidino-2-phenylindole dihydrochloride–stained nuclei (blue) is shown. The EMT score is indicated on
the left, with descriptions of the characteristics of EMT biomarker staining relative to changes in epithelial
architecture on the right. The score incorporates (1) the location and amount of vimentin-positive (mesen-
chymal marker) cell staining within the epithelium and (2) decreased cytokeratin (epithelial marker) staining
in hyperplastic epithelium.
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ulation, an EPX index was assigned (by C.A.P.) to each subject’s biopsy spec-
imen, as previously described.15Fibrosis index
Hematoxylin and eosin–stained sections were used to assess the degree of
fibrosis in esophageal biopsy specimens. A fibrosis score of 0 to 2 was
assigned by 3 independent blinded observers (S.A.W., V.M., and J.C.M.)
based on the number of fibroblasts, thickness, and the character of collagen
bundles and collagen accumulation, as previously described.8 A fibrosis score
of 0 indicated loose, lacy individual collagen fibrils; a score of 1 indicated
more densely packed collagen fibrils along the basal lamina with loss of indi-
vidual laciness but further away from the basal lamina normalized to lacy in-
dividual fibrils; and a fibrosis score of 2 indicated tightly packed collagen
fibrils with individual fibrils no longer evident (see Fig E1 in this article’s On-
line Repository at www.jacionline.org).TGF-b1 immunohistochemistry: TGF-b1 index
Sections from esophageal biopsy specimens were stained with anti–TGF-
b1 antibody (catalog no. 500-M66; Peprotech, Rocky Hill, NJ), as previously
described,16 and scored by 3 independent blinded observers (S.A.W., V.M.,and J.C.M.). A 3-point scoring system was used based on staining of the epi-
thelium. A score of 1 (mild staining) corresponded to blue/light brown epithe-
lium, a score of 2 (moderate staining) corresponded to darker brown
epithelium, and a score of 3 (severe staining) corresponded to dark brown
staining throughout the entire epithelium.Statistical analyses
Data were analyzed by using ANOVA with the Bonferroni multiple
comparisons test or the 2-tailed Student t test. Differences between means
were considered significant at a P value of less than .05. Relationships be-
tween the EMT index, eosinophil counts, and staining indices for EPX, fi-
brosis, and TGF-b were analyzed by using the Pearson test; correlation
coefficients (r values) were considered significant at a P value of less
than .05.RESULTS
EMT is induced by TGF-b in cultured esophageal
epithelial cells
To determine whether esophageal epithelium has the capacity
to undergo EMT, we analyzed the ability of TGF-b1 to induce
FIG 2. Induction of mesenchymal genes in esophageal epithelial cells in culture: evidence for EMT in vitro.
Analysis of adhesion molecules and cytoskeletal component expression representative of epithelial cells
(E-cadherin, cytokeratin 8, and cytokeratin 14) and mesenchymal cells (N-cadherin, vimentin, and fibronec-
tin) in HET-1A cells after 24 and 48 hours of culture with TGF-b1 (5 ng/mL) is shown. Data are expressed as
mean 6 SD relative mRNA abundance compared with that in untreated control subjects, as determined by
using RT-Q-PCR. Statistical significance was assessed by using the Student t test compared with untreated
control subjects at 24 and 48 hours. *P < .05, **P < .01, and ***P < .001 (n 5 5-7 per group).
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ture of HET-1A cells with TGF-b1 decreased gene transcription
for epithelial biomarkers, including adhesion proteins and cyto-
skeletal components representative of the epithelial phenotypes
cytokeratin 8 (22% decrease, P < .01) and cytokeratin 14 (44%
decrease, P 5 .27; Fig 2). Correspondingly, increased mRNA
expression for a number of biomarkers representative of the me-
senchymal phenotype, including N-cadherin (adhesion; 3.3-fold,
P < .001), vimentin (cytoskeletal; 2.1-fold, P < .001), and fibro-
nectin (extracellular matrix; 7.5-fold, P < .001), was detected
(Fig 2), all of which are gene expression changes characteristic
of metastable EMT.17-19EMT is present in esophageal tissue from subjects
with active EoE
Clinical characteristics of the 60 subjects studied based on
diagnostic criteria are shown in Table I. Subjects ranged from 8
months to 22 years old with a duration of symptoms ranging from
2 months to 7 years. Treatment histories for subjects with active
EoE included PPIs, TCs, and elimination of allergenic foods,
whereas subjectswithnormal esophagus,GERD,and indeterminate
EoE had only been treated with PPIs. Pretreatment and posttreat-
ment biopsy specimens froman additional 18 randomly selectedpe-
diatric subjects with EoE were analyzed to determine the effect of
treatments for EoE on EMT. Patients ranged in age from 6 to 13
TABLE I. Clinicopathologic characteristics of the subject study groups
Patients with normal
esophagus Patients with GERD
Patients with EoE
(indeterminate)* Patients with EoE
No. (n 5 60) 21 7 15 17
Sex (male/female) 10/11 7/0 8/7 10/7
Age range 8 mo-15 y 1-18 y 22 mo-21 y 1-15 y
Duration of symptoms 3 mo-6 y 2 mo-2 y 1 d-3 y 1-7 y
Previous treatments Zantac (ranitidine), Prevacid
(lansoprazole), Prilosec
(omeprazole), Reglan
(metoclopromide), Zyrtec
(cetirizine), Miralax
(polyethylene glycol)
Zantac, Prevacid, Prilosec,
Protonix (pantoprazole)
None, unknown, Zantac,
TUMS, Prevacid
Zantac, Prevacid, Prilosec,
swallowed Flovent
(fluticasone), Singulair,
elimination of foods
identified as allergic
No. of eosinophils
(peak/hpf range)
0-2 0-30 0-87 7-123
Demographic and clinical features of the 60 subjects evaluated for EMT, fibrosis, TGF-b, EPX index, and eosinophil counts. The subject groups include patients undergoing a
clinically indicated endoscopy with biopsy but with an otherwise histologically normal esophagus and those with recorded diagnoses of GERD, indeterminate EoE, and EoE.
*EoE (indeterminate) represents subjects who had many clinical features of EoE but lacked the threshold number of greater than 15 eosinophils/hpf or had no documented
treatment with acid suppression.1,14
FIG 3. Immunofluorescent staining for EMT in subject study groups. Immunofluorescent staining for
cytokeratin (epithelial marker, green) and vimentin (mesenchymal marker, red) in the epithelium with 49-6-
diamidino-2-phenylindole dihydrochloride nuclear counterstaining (blue) is shown. Representative confo-
cal images from esophageal biopsy specimens of subjects with EoE, indeterminate EoE, GERD, and normal
esophagus are shown. Quantitative assessment of the EMT index for these subject groups is shown in Fig 4.
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ment). Subjects’ clinical symptoms had resolved, and histopatho-
logic remission of their EoE was defined as 10 or fewer
eosinophils/hpf with normalization of epithelial hyperplasia.
Tissue sections were dual stained for the EMT biomarkers
cytokeratin (epithelial) and vimentin (mesenchymal) to deter-
minewhether EMToccurred in the esophageal mucosa of subjects
with EoE (Fig 3). Vimentin-positive cells were present within thelamina propria, which is consistent with fibroblasts, myofibro-
blasts, or both. Importantly, vimentin-positive cells were visual-
ized within the hyperplastic epithelium (Fig 3), which is
consistent with the process of EMT.17,19 A small number of
vimentin-positive cells were also cytokeratin positive, suggesting
cells in transition between epithelial and mesenchymal pheno-
types, a characteristic feature of EMT, but these were infrequent
and more difficult to visualize (see Fig E2 in this article’s Online
FIG 4. Quantitative assessment of EMT in subjects with EoE, GERD, and
normal esophagus. Mean 6 SD EMT scores for the 4 subject groups are
shown. The highest EMT index was associated with EoE, followed by
indeterminate EoE > GERD > normal esophagus. The mean for the normal
esophagus control group was right skewed; that is, more values were
closer to an EMT score of zero, whereas the mean for EoE was slightly left
skewed. The level of EMT in subjects with EoE was not significantly
different from that seen in the indeterminate EoE group, whereas both of
these subject groups had significantly greater EMT scores than the GERD
and normal esophagus groups. Comparative EMT scores for the 2 inde-
pendent observers are shown in Table E2.NS, Not significant. **P < .01 and
***P < .001.
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tin-positive, mesenchymal-like cells were found most commonly
in tissues from subjects with active EoE (12/17 [70.6%]) and
indeterminate EoE (11/15 [73.3%]) compared with tissues
from subjects with GERD (1/8 [12.5%]) or normal esophagus
(0/21, Fig 3). Tissues from subjects with active EoE or indeter-
minate EoE, but not GERD or normal esophagus, had markedly
decreased epithelial staining for cytokeratins coupled with
vimentin-positive cells within the epithelium, a characteristic ap-
pearance of EMT (Fig 3) and representative of a score of 5 on the
6-point EMT scale (Fig 1). EMT scores were significantly higher
in tissues of subjects with active EoE (3.08 6 0.25) and indeter-
minate EoE (2.70 6 0.31) compared those of subjects with
GERD (1.71 6 0.33) or normal esophagus (1.28 6 0.15, Fig 4
and see Table E2 in this article’s Online Repository at www.
jacionline.org).
EMT correlates with measures of eosinophilic
inflammation
Because eosinophils are potent sources of remodeling factors
associated with EMT, such as TGF-b, we quantitated the eosin-
ophil burden associated with active EoE and correlated it with
EMT scores. Consistent with previous studies, mean 6 SEM
eosinophil counts and EPX scores from tissues of subjects with
active EoE (46.2 6 6.9 eosinophils/hpf and 43.4 6 1.9 EPX
score) and indeterminate EoE (31.5 6 7.9 eosinophils/hpf and
40.96 2.1 EPX score) were significantly greater than those from
subjects with GERD (5.0 6 4.2 eosinophils/hpf and 14.6 6 5.9
EPX score) and normal esophagus (0.26 0.1 eosinophils/hpf and
2.7 6 1.2 EPX score, see Table E2). Comparison of subjects’
EMT scores with peak eosinophil counts per hpf (Fig 5, A, top)
and EPX index (Fig 5, A, bottom) identified significantcorrelations for both eosinophils (r5 0.691, P <.01) and EPX in-
dex (r 5 0.738, P < .01).EMT correlates with esophageal subepithelial
fibrosis
We analyzed correlations between EMT scores and indices of
subepithelial fibrosis and TGF-b1 expression in esophageal
biopsy specimens from the EoE and other study groups. The
mean 6 SEM fibrosis index was significantly greater in tissues
from subjects with EoE (1.67 6 0.14) and indeterminate EoE
(1.47 6 0.19) compared with that seen in subjects with GERD
(0.29 6 0.3) and normal esophagus (0.26 6 0.13; P < .001, EoE
vs GERD; P < .001, EoE vs normal esophagus; P < .01,
indeterminate EoE vs GERD; and P < .001, indeterminate EoE
vs normal esophagus; see Table E2). Of note, EMT scores were
significantly correlated with the fibrosis index (r 5 0.644, P <
.01; Fig 5, B, top). Similarly, the TGF-b index was significantly
higher in subjects with active EoE (2.33 6 0.16) and indetermi-
nate EoE (2.0 6 0.24) compared with that seen in subjects
with GERD (1.14 6 0.34) or normal esophagus (1.09 6 0.14;
P < .01, EoE vs GERD; P < .001, EoE vs normal esophagus;
not significant for indeterminate EoE vs GERD; and P < .01, in-
determinate EoE vs normal esophagus; see Table E2). In addition,
EMT scores were significantly correlated with the TGF-b index
(r 5 0.520, P < .01; Fig 5, B, bottom).Treatment of EoE resolves EMT
EMT was quantitated in esophageal biopsy specimens before
and after treatments known to induce clinicopathologic remis-
sion to determine whether treatment affects esophageal EMT in
children with EoE (Fig 6, A, and see Table E3 in this article’s
Online Repository at www.jacionline.org). After treatment,
EMT scores decreased significantly in all subjects (3.17 6
0.17 before treatment vs 0.82 6 0.09 after treatment). Analysis
of EMT with respect to individual treatments (n 5 6 subjects
per group) showed similarly decreased EMT scores for sub-
jects treated with TCs (2.77 6 0.92 before treatment vs 0.88 6
0.61 after treatment, a 68.2% decrease; P < .001), SFED
(3.49 6 0.71 before treatment vs 0.99 6 0.25 after treatment,
a 72.8% decrease; P < .001), and ED (3.25 6 0.76 before
treatment vs 0.61 6 0.18 after treatment, an 81.2% decrease;
P < .001).
EMT scores were compared with peak eosinophil counts in
biopsy specimens obtained from all 18 subjects before and after
treatment to determinewhether resolution of EMTwas associated
with a decrease in eosinophil counts. There was a strong positive
correlation of EMT with subjects’ peak eosinophil counts per
hpf for the combined EoE treatment groups (r5 0.804, P < .001,
n 5 36; Fig 6, B) and within individual treatment groups (TCs,
r 5 0.868; SFED, r 5 0.857; ED, r 5 0.820; all P < .001; all
n5 12; Fig E3 and see Table E4 in this article’s Online Repository
at www.jacionline.org).DISCUSSION
Because esophageal tissue can demonstrate significant epithe-
lial basal zone hyperplasia and subepithelial fibrosis in subjects
with EoE, we hypothesized that EMT might be one of the
processes associated with these remodeling events. Our results
A B
FIG 5. EMT scores correlate with measures of esophageal eosinophil counts and staining for EPX and with
subepithelial fibrosis and staining for TGF-b. EMT scores per hpf were analyzed for relationships to
subjects’ peak numbers of esophageal eosinophils/hpf (top) and staining index for EPX (bottom; A) and fi-
brosis index (top) and TGF-b staining index (bottom; B) for all 60 subjects in the subject groups. The Pearson
correlation coefficient (r) and its associated statistical significance are shown for all 60 subjects (dot plot
with symbols) comprising the subject groups, including EoE (solid circles), indeterminate EoE (solid trian-
gles), GERD (open circles), and normal esophagus (solid diamonds). The trend line for the mean indices
(solid squares) is also shown (solid line).
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showed that treatments that resolve eosinophilic inflammation
and epithelial hyperplasia reverse EMTand subepithelial fibrosis.
We also showed that the degree of EMT and its resolution in
subjects with EoE are strongly correlated with the load of tissue
eosinophils within the esophagus.
Esophageal remodeling with subepithelial fibrosis occurs in
both children and adults with EoE.6-8,20,21 Histologically, the
subepithelial space is occupied by increased collagen deposi-
tion, and by using endoscopic ultrasonography, several studies
have demonstrated significant thickening of the mucosa, submu-
cosa, and muscularis that is suggestive of fibrosis.4,22,23 Most re-
cently, Straumann et al24 used endoscopic ultrasonography to
show that there was marked thickening of these esophageal
layers in adolescents and adults with long-term EoE (symptoms
for 9.3 6 5.2 years), leading to speculation that in some patients
the chronic unbridled inflammation seen with EoE results in fi-
brosis and remodeling. Molecular support for remodeling arises
from studies showing that there is increased expression of TGF-
b1 and its downstream signaling molecules phospo-SMAD2/3
in association with subepithelial fibrosis and esophageal stric-
ture formation.8,25,26 TGF-b1–expressing cells include eosino-
phils8 and mast cells.25 Thus current evidence suggests that
increased expression of and signaling by profibrotic TGF-b1
is key to the induction of esophageal fibrosis in subjects with
EoE.6
The origins of mesenchymal cells (fibroblasts and myofibro-
blasts) participating in tissue repair during chronic inflammationand tissue damage, notably fibrosis, are still poorly understood.
Emerging evidence from fields including allergic diseases and
asthma suggests that EMT contributes to the genesis of disease-
related fibroblasts and myofibroblasts and development of tissue
fibrosis, representing a significant source of these fibrogenic
cells.9,11,27,28 We demonstrated the presence of vimentin-positive
mesenchymal-like cells in the context of loss of normal epithelial
architecture and decreased expression of cytokeratins within
hyperplastic epithelium in a majority of our subjects with active
EoE compared with those with GERD or normal esophagus.
We also showed that these changes, which are characteristic of
EMT, are directly proportional to the eosinophil load in esopha-
geal biopsy specimens.
EMT participates in the genesis of tissue and organ fibrosis in
the kidney, liver, and lung in response to chronic injury and repair
by contributing to the population of disease-related fibroblasts
and myofibroblasts that overproduce extracellular matrix.9,29,30
These responses are regulated in part by exogenous sources, auto-
crine sources, or both and signaling by TGF-b in epithelial
cells.18,29 The presence of EMT in subjects with EoE was highly
correlated with the index of subepithelial fibrosis, eosinophil
presence, and state of activation (determined based in both cell-
associated and secreted expression of EPX) and the presence of
TGF-b1 in the biopsy specimens, thus providing compelling sup-
port that EMT contributes to the genesis of subepithelial fibrosis
in subjects with EoE. A number of growth factors induce or
regulate the development of EMT, primarily TGF-b, with others
being more variable and context dependent, such as fibroblast
FIG 6. Resolution of esophageal EMT in subjects with EoE after treatment: correlation with eosinophil load.
A, The presence/amount of EMT was scored in subjects with EoE treated with 3 different modalities that re-
duce epithelial eosinophilic inflammation. Mean6 SD EMT scores before and after treatment are shown for
all treated subjects combined (n5 18) and for individual treatment groups (n5 6 per group; see Table E3 for
the percentage reduction in EMT). B, Resolution of esophageal EMTwas directly correlated with the number
of esophageal eosinophils before and after treatments that reduced the esophageal eosinophil burden (Rx).
The correlation coefficient (r) and associated significance is shown for the relationship between all 18 EoE
subjects’ pretreatment and posttreatment EMT scores and peak eosinophil counts (combined n 5 36). The
vertical dashed line delineates pretreatment from posttreatment eosinophil counts/EMT scores (see Table
E4 and Fig E3 for correlations within each of the individual treatment groups). **P < .01 and ***P < .001.
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tor 2, and hepatocyte growth factor.18,31 Of these, TGF-b, either
induced by autocrine expression within epithelial cells them-
selves in response to tissue damage or from a paracrine inflamma-
tory cell source, plays a key role in inducing EMT and is vital to
expression of the EMT proteome.18,19,32
We showed here that TGF-b1 induces changes in gene expres-
sion in vitro in an esophageal epithelial cell type, HET-1A cells, in
a manner consistent with EMT. Importantly, TGF-b1 potently
induced transcription of mesenchymal genes (N-cadherin, vimen-
tin, and fibronectin) and downregulated expression of cytokeratins
in HET-1A esophageal cells, which are characteristic findings for
the induction of EMT in primary and epithelium-derived cell lines
from other tissues and organs.18,29,33,34 Previous studies of TGF-b
family–induced EMT in culture showed that although phospho-
Smad signaling occurs rapidly, induction of transcriptional repres-
sors associated with induction of EMT does not occur until 48
hours, and subsequent repression of epithelial markers, such as
E-cadherin, at both themRNAand protein levels takes even longer
(up to 72 hours).35 Loss of epithelial phenotypewith dissolution of
tight polarized cell-cell adhesion might be a gradual or even re-
versible process36 or might be regulated posttranslationally by
proteases, including metalloproteases, as shown for EMT-
processes associated with tumorigenesis.37 A number of studies
showed simultaneous expression of both epithelial andmesenchymal adherens junction proteins in primary and meta-
static tumors, but functional studies suggest the metastatic inva-
sive phenotype of mesenchymal N-cadherin prevails over stable
polarized E-cadherin when they are coexpressed.38,39 Thus al-
though HET-1A cells coexpressed epithelial and mesenchymal
markers in the current study, the mesenchymal phenotype might
prevail, allowing this gradual EMTprocess to contribute to the de-
velopment of subepithelial fibrosis in the esophagus in subjects
with EoE.
Eosinophils, in addition to direct contribution of TGF-b for
induction of EMT, can induce expression of EMT- and fibrosis-
relevant remodeling factors in epithelial cells themselves, includ-
ing TGF-b and others (endothelin-1, TGF-a, platelet-derived
growth factor AB, epidermal growth factor receptor, matrix
metalloproteinase 9, IL-6, IL-11, fibronectin, and tenascin),
through secretion of their granule cationic proteins (major basic
protein 1 and EPX)40,41 or cytokines (IL-13).42,43 Increased TGF-
b1 expression, previously shown in pediatric subjects with
EoE,8,44 was also demonstrated in the current study, providing
further evidence for its role and that of EMT in inducing esopha-
geal fibrosis in subjects with EoE. Importantly, the relevant cellu-
lar sources of TGF-b (eosinophils, mast cells, epithelial cells, and
fibrocytes), the mechanisms by which TGF-b in the esophagus in
subjects with EoE becomes activated from its latent form (through
integrin avb6-mediated11,45 or proteolytic pathways), and the
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and its resolution46 remain to be determined in subjects with EoE.
For the 18 children with active EoE who were successfully
treated with 3 different treatment modalities (TCs, SFED, and
ED), their decreased posttreatment EMT scores were significantly
correlated with their reduced esophageal eosinophil load. How-
ever, we were unable to assess a corresponding posttreatment
decrease in the levels of fibrosis in these subjects with EoE
because there was insufficient lamina propria (<2 mm) present in
many of the esophageal biopsy specimens to allow quantitation of
the fibrosis index. However, several studies previously showed
that TC treatment decreases or completely resolves esophageal
fibrosis in children with EoE.6,25 Thus in addition to these earlier
reports of decreased subepithelial fibrosis with steroid treatment,
the present study shows a corresponding decrease in the amount
of EMT that likely contributes to the fibrogenesis characteristic
of subjects with EoE.
EoE is a chronic inflammatory disorder,21 and remission of
EoE inflammation results in resolution of EMT (current study)
and fibrosis.44 Current therapies, either pharmacologic with
TCs or dietary restrictions (SFED and ED), are effective for in-
ducing disease remission, but maintaining remission long-term
is difficult because disease recurs once the treatment is discontin-
ued. For example, TCs are effective in many but not all subjects
with EoE in inducing clinicopathologic remission, but relapse
rates are high once the corticosteroid is discontinued.47 Currently,
there are no recommendations for low-dose maintenance therapy
with TCs that will maintain subjects in remission and thereby pre-
vent fibrosis.1 A recent study in adults showed that low-dose
maintenance treatment with budesonide was well tolerated, and
50% of patients were maintained in remission after a 50-week
treatment period.24 However, after 50 weeks of low-dose budeso-
nide, submucosal and muscularis propria thickening still per-
sisted, fibrosis scores were increased slightly, and TGF-b and
tenascin C levels were still increased. Additionally, long-term
low-dose budesonide therapy was associated with significant
reductions in overall mucosal but not epithelial thickness, and
esophageal remodeling showed only a trend toward normaliza-
tion.24 Finally, 1 year of topical fluticasone treatment of adults
with EoE led to a nonsignificant reduction in subepithelial fibro-
sis.20 Taken together, these findings suggest that low-dose contin-
uous TCs might be unable to prevent the progression of
esophageal fibrosis, supporting the need to explore alternative
long-term treatmentmodalities to block fibrogenesis of the esoph-
agus in subjects with EoE.
Finally, we analyzed a group of pediatric patients with an
indeterminate diagnosis of EoE and found their EMT scores to be
virtually identical to those of patients with confirmed EoE.
Clinical experience is identifying an increasing number of these
kinds of children and adults with features highly suggestive of
EoE but who do not reach the requisite eosinophil threshold
number.1 Reasons for this might include limitations in biopsy
sampling, a later more chronic stage in the inflammatory process,
a different EoE phenotype, or amore fibrotic phenotype ofGERD.
Future studies that provide additional clinical andmolecular char-
acterization will help clarify this patient population more fully.
In conclusion, correlations of EMTwith esophageal eosinophil
counts, their state of activation, and measures and mediators of
fibrosis suggest that EMT contributes significantly to the subep-
ithelial fibrosis characteristic of EoE. Thus treatments affecting
esophageal eosinophilia in subjects with EoE can alter the naturalhistory of the disease in terms of reversing esophageal remodel-
ing. Prospective studies are needed to extend these findings
to further define the profibrotic mediators and signaling cascades
that propagate esophageal epithelial reactions in subjects with
EoE, leading to EMT and factors, such as bone morphogenic
protein 7, that might be involved in its resolution with
treatment.48,49
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support and Christine Jun, MD, at UIC COM for participation in preliminary
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Key messages
d Esophageal epithelial cells can undergo TGF-b–induced
EMT, a process associated with tissue and organ fibrosis,
including the subepithelial fibrosis associated with airway
remodeling in asthmatic subjects.
d Fibrosis-associated EMT occurs in the esophagi of chil-
dren with active EoE but not in children with other
esophageal diseases, such as GERD.
d The degree of EMT in the esophagus in subjects with EoE
is highly associated with the amount of subepithelial fibro-
sis, numbers and measures of activation of esophageal
eosinophils, and levels of remodeling factors, such as
TGF-b.
d Esophageal EMT resolves with EoE treatments that sig-
nificantly decrease the esophageal burden of eosinophils.
d EoE treatments that significantly reduce esophageal
eosinophil counts are likely to alter the natural history
of this food-induced allergic disease by reversing EMT-
associated fibrogenesis.
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FIG E1. Three-point fibrosis assessment scale in esophageal biopsy specimens. Representative hematox-
ylin and eosin staining of esophageal mucosa. The fibrosis score (0-2) is indicated on the left, with descrip-
tions of the scoring system on the right.
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FIG E2. Evidence for EMT in subjects with EoE: presence of mesenchymal
(vimentin-positive) cells in the hyperplastic epithelium. Tissue section from
a subject with active EoE stained for cytokeratin (epithelial marker, green)
and vimentin (mesenchymal marker, red) by using immunofluorescence,
with 49-6-diamidino-2-phenylindole dihydrochloride nuclear counterstain-
ing (blue). The dashed white line delineates the epithelial basement mem-
brane/lamina propria boundary. The white arrows show abnormally
present vimentin-positive cells within a region of epithelium (E) near the
basal zone showing decreased expression of cytokeratin, a characteristic
feature of EMT. The green arrow indicates a rare cell stained for both
vimentin and cytokeratin. There are numerous vimentin-positive cells
(fibroblasts) in the lamina propria (LP). The bar indicates 20 mm in this
3630 confocal image.
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FIG E3. The resolution of esophageal EMT correlates with the number of esophageal eosinophils before
and after treatments that reduced the esophageal eosinophil burden in subjects with EoE. Pearson
correlation analysis (r) and associated significance (P value) are shown for EMT scores versus peak eosin-
ophil counts (n 5 6 pretreatment and n 5 6 posttreatment values in each group) for subjects treated with
swallowed corticosteroids (A), SFED (B), and ED (C). The vertical dashed lines delineate pretreatment (right
of line) from posttreatment (left of line) eosinophil counts/EMT scores.
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TABLE E1. TaqMan probes used for RT-Q-PCR of EMT biomarker
genes
Gene name Protein TaqMan probe ID
CDH1 E-cadherin Hs01023895_m1
CDH2 N-cadherin Hs00169953_m1
VIM Vimentin Hs00958112_g1
FN Fibronectin Hs00365058_m1
KRT8 Cytokeratin 8 Hs01595539_g1
KRT14 Cytokeratin 14 Hs00265033_m1
The indicated EMT biomarker mRNA transcripts were assessed by using the TaqMan
Gene Expression Assay FAM dye-labeled TaqMan MGB probes (Applied Biosystems)
and ABsolute Blue QPCR ROX MasterMix (Thermo Scientific).
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TABLE E2. Quantitative indices for EMT, fibrosis, TGF-b, EPX, and eosinophils in the subject and control groups
Parameter
Control subjects with
normal esophagus Subjects with GERD
Subjects with EoE
(indeterminate)
Subjects with EoE
(confirmed)
No. (n 5 60) 21 7 15 17
EMT scores
Observer 1 1.06 6 0.15 1.62 6 0.39 2.70 6 0.33 3.08 6 0.31
Observer 2 1.41 6 0.17 1.79 6 0.27 2.60 6 0.28 3.08 6 0.26
Mean EMT 1.28 6 0.15 1.71 6 0.33 2.7 6 0.31 3.08 6 0.25
Eosinophils (peak)* 0.2 6 0.1 5.0 6 4.2 31.5 6 7.9 46.2 6 6.9
EPX index 2.7 6 1.2 14.6 6 5.9 40.9 6 2.1 43.4 6 1.9
Fibrosis index 0.26 6 0.13 0.29 6 0.29 1.47 6 0.19 1.67 6 0.14
TGF-b index§ 1.09 6 0.14 1.14 6 0.34 2.0 6 0.24 2.33 6 0.16
Mean 6 SEM indices are shown for quantitative measurements of EMT levels, subepithelial fibrosis, EPX index (eosinophils and secreted EPX), TGF-b index, and peak
eosinophil counts. For the EMT index, evaluations by 2 independent observers using the 6-point EMT scoring system (Fig 1) are shown. The EoE (indeterminate) group represents
subjects who had many clinical features of EoE but lacked the threshold number of greater than 15 eosinophils/hpf or had no documented treatment with acid suppression.1,14
Statistical comparisons between means are as follows (for EMT, see Fig 4).
*Eosinophils/hpf: not significant, normal esophagus vs subjects with GERD; P < .001, normal esophagus versus indeterminate EoE; P < .001, normal esophagus versus subjects
with EoE; not significant, GERD versus indeterminate EoE; P < .001, GERD versus EoE; not significant, indeterminate EoE versus EoE.
EPX index: P < .05, normal esophagus versus GERD; P < .001, normal esophagus versus indeterminate EoE; P < .001, normal esophagus versus EoE; P < .001, GERD versus
indeterminate EoE; P < .001, GERD versus EoE; not significant, indeterminate EoE versus EoE.
Fibrosis index: not significant, normal esophagus versus GERD; P < .001, normal esophagus versus indeterminate EoE; P < .001, normal esophagus versus EoE; P < .01, GERD
versus indeterminate EoE; P < .001, GERD versus EoE; not significant, indeterminate EoE versus EoE.
§TGF-b index: not significant, normal esophagus versus GERD; P < .01. normal esophagus versus indeterminate EoE; P < .001, normal esophagus versus EoE; not significant,
GERD versus indeterminate EoE; P < .01, GERD versus EoE; not significant, indeterminate EoE versus EoE.
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TABLE E3. Comparison of EMT scores before and after treatment
of subjects with EoE
Treatment
(no. of patients)
EMT scores
Pretreatment Posttreatment
Decrease
in EMT (%)
P
value
All (18) 3.17 6 0.82 0.82 6 0.39 74.1 <.001
Steroid (6) 2.77 6 0.92 0.88 6 0.61 68.2 <.01
SFED (6) 3.49 6 0.71 0.95 6 0.25 72.8 <.001
Elemental (6) 3.25 6 0.76 0.61 6 0.18 81.2 <.001
Mean 6 SD EMT scores are shown for all subjects combined and individual treatment
groups before and after treatment. The percentage decrease in the EMT score is
indicated, as is the P value for the difference between the pre- and post-EMT means.
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TABLE E4. Correlations between EMT scores and peak eosino-
phil counts before and after treatment in subjects with EoE
Treatment r value P value
All (18) 0.827 <.001
Steroids (6) 0.853 <.001
SFED (6) 0.893 <.001
Elemental (6) 0.822 <.001
Pearson correlation coefficients (r) and their associated statistical significance (P
values) are shown for all subjects combined (graphically presented in Fig 6) and for
the individual treatment groups for subjects’ pretreatment (n 5 6) and posttreatment
(n 5 6) EMT scores and corresponding peak eosinophil counts (shown graphically in
Fig E3).
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